Contraindicated (1)pentobarbital will reduce the level or impact of cariprazine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is accountable for the formation and elimination of cariprazine's active metabolites.

pentobarbital will lessen the extent or effect of meloxicam by affecting hepatic enzyme CYP2C9/10 metabolism. Slight/Importance Not known.

pentobarbital will lessen the level or impact of vincristine liposomal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.

pentobarbital will lower the level or effect of capivasertib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Powerful or moderate CYP3A inducers minimize capivasertib exposure, which may cut down efficacy.

CYP3A4 inducers may perhaps increase the development of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely keep track of individuals having ifosfamide with CYP3A4 inducers for toxicities and think about dose adjustment.

Extended or recurring exposure may well bring about destructive effects on fetal or younger children’s brain growth

Prevent; coadministration with CYP3A inducers may lead to lowered plasma concentrations of elvitegravir and/or simply a concomitantly administered protease inhibitor and lead to loss of therapeutic effect and to achievable resistance

pentobarbital will reduce the level or result of pazopanib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will minimize the website level or influence of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

Barbiturates could cause fetal destruction when administered to some pregnant girl; retrospective, circumstance-controlled reports have suggested a link involving maternal use of barbiturates and a higher-than-anticipated incidence of fetal abnormalities

Check Closely (one)pentobarbital will lower the extent or effect of mestranol by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will lessen the extent or result of eucalyptus by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Mysterious.

pentobarbital will lower the level or outcome of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

pentobarbital will reduce the extent or impact of voriconazole by influencing hepatic enzyme CYP2C9/10 metabolism. Minor/Importance Unidentified.